Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B.

ABSTRACT:

Background & aims

Predicting the long-term HBsAg seroclearance, an ideal endpoint, is relevant for decision-making regarding antiviral therapy for patients with chronic hepatitis B (CHB). This study aimed to identify predictors and develop a prediction model for HBsAg seroclearance in patients with HBeAg-negative CHB.

Methods

A total of 2,032 untreated HBeAg-negative patients who underwent a 2-year baseline observation period were enrolled. Prediction models were developed using independent predictors of seroclearance, and their performance was evaluated through internal and external validation using an independent cohort of 753 patients, along with sensitivity analyses.

Results

The estimated annual incidence of HBsAg seroclearance was 2.22% (15,508 person-years).

SUBMITTER: Lee HL 

PROVIDER: S-EPMC12167479 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature